G1 Therapeutics, Inc.
GTHX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 1.22 | 0.09 | 0.00 |
| FCF Yield | -4.07% | -3.75% | -8.09% | -14.19% |
| EV / EBITDA | -61.95 | -29.63 | -20.78 | 1.00 |
| Quality | ||||
| ROIC | -4.87% | -12.10% | -10.60% | -17.32% |
| Gross Margin | 95.57% | 92.55% | 91.56% | 74.99% |
| Cash Conversion Ratio | 0.96 | 0.87 | 1.18 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.42% | 51.52% | 37.88% | 22.64% |
| Free Cash Flow Growth | 40.73% | 30.44% | -20.94% | -175.09% |
| Safety | ||||
| Net Debt / EBITDA | -12.52 | -3.04 | -2.83 | 5.96 |
| Interest Coverage | -1.30 | -4.57 | -4.20 | -7.74 |
| Efficiency | ||||
| Inventory Turnover | 0.05 | 0.09 | 0.10 | 0.23 |
| Cash Conversion Cycle | 1,082.53 | 692.95 | 682.27 | 247.91 |